BioNJ and Publicis Healthcare Communications Group Partner On Forum to Explore Complex Biosimilar Issues

New York, NY, June 6, 2011—As billions of biotech products are set to go off patent, Congress and industry look to biosimilar legislation to guide next steps.  Publicis Healthcare Communications Group (PHCG) and BioNJ convened a panel of top industry experts to discuss “Biosimilars and Protecting R&D Dollars” on June 2, 2011 in Bridgewater, New Jersey.

“Innovator and imitator companies see biosimilars as territory for expanded patient care and economic opportunity,” said Nick Colucci, CEO and President of PHCG and moderator of the morning session that included industry experts.  “As strategic partners to the biopharma industry, we seek to share understanding of the pivotal issues, from interchangeability to immunogenicity to affordability.”

Companies engaged in biosimilars are expected to reap $3.7 billion by 2015, however, a successful model for R&D and market access has yet to be created.  With the U.S. Food and Drug Administration guidance on the regulatory pathway for biosimilar approval expected later this year, companies are clamoring for insight on product development, marketing, and potential business opportunities. PHCG and BioNJ recognized the need for bringing experts together with attendees to discuss the ever-changing and evolving requirements within the industry.

Covering industry, academia, and specialty pharmacy, presenters were among the most respected and noted experts in the biosimilars space, providing expertise in strategy, access, regulatory complexities, and reimbursement considerations.  Panelists included:

  • Gillian Cannon, PhD, Vice President, BioVentures, Merck
  • Michael Castagna, PharmD, Executive Director, Orencia, Bristol-Myers Squibb
  • Joseph Fuhr Jr., PhD, ACI Senior Fellow and professor of Economics at Widener University
  • James Langley, Former Senior Vice President of Reimbursement, Accredo Health Group
  • Shefali Kakar, PhD, Senior Fellow, Oncology Clinical Pharmacology, Novartis

“This briefing is part of BioNJ’s mission to advance the ability of biotechnology and related industries in New Jersey to serve the larger society,” said Debbie Hart, CAE, APR, President of BioNJ. “We’re appreciative of partners like PHCG, who mobilize leading industry minds for the benefit of our members and the health professional community.”

BioNJ will be providing the presentations available for download at https://www.bionj.org/events/biosimilars-breakfast-briefing.

###

About Publicis Healthcare Communications Group

Publicis Healthcare Communications Group (PHCG) is the largest health-oriented agency network in the world.  A division of Publicis Groupe S.A., PHCG manages top-tier agencies promoting innovative solutions in advertising, medical education, sales and marketing, digital, market access, and medical and scientific affairs.  PHCG is dedicated to delivering ideas of purpose that compel action, change lives, and amplify business outcomes.  With more than 3,000 employees, PHCG manages nearly 20 agency brands through 45 offices located in 11 countries.  For more information, visit:  www.publicishealthcare.com

About BioNJ

With more than 300 member companies, BioNJ is singularly focused on the growth and prosperity of New Jersey’s biotechnology cluster.  Founded in 1994 by New Jersey industry CEOs, BioNJ serves as the voice of biotechnology companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate to New Jersey. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.  To learn more about BioNJ, please visit www.BioNJ.org.